Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
OBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.37 - $7.04
Previous CloseN/A
Volume15.92K
Average Volume (3M)362.67K
Market Cap
$130.23M
Enterprise Value$101.81M
Total Cash (Recent Filing)$49.88M
Total Debt (Recent Filing)$16.44M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Nov 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,057,190
10 Day Avg. Volume499,620
30 Day Avg. Volume362,666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue35.28
Enterprise Value/Gross Profit38.10
Enterprise Value/Ebitda-1.48
Forecast
1Y Price Target
$8.83Price Target Upside225.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial SupportLigand Pharmaceuticals will provide Orchestra BioMed with $20M in funding and purchase $5M of OBIO shares, with an additional $15M possible if milestones are met.
Regulatory MilestonesThe FDA has granted Breakthrough Device designation for atrioventricular interval modulation (AVIM) therapy.
Strategic PartnershipsOrchestra BioMed announced new strategic partnerships with Ligand Pharmaceuticals and Medtronic, indicating potential growth opportunities.
Bears Say
Financial ChallengesThe company may need to raise additional capital within the next 12 months, indicating a potential financial challenge.
Financial PerformanceNet loss was $18.8M, or ($0.49) per share, moderately higher than our estimated loss of $15.5M.
Risks And UncertaintiesRisks include failure of product candidates in clinical trials, failure to secure regulatory approval, and potential dilution risk, which could impact the company's future valuation.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.37 and its highest was $7.04 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $130.23M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Nov 18, 2025 which is in 98 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Currently, no data Available
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 48,057,190 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.83 (225.83% Upside)
$8.83 (225.83% Upside)
Blogger Sentiment
Neutral
OBIO Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.06%
12-Months-Change
Fundamentals
Return on Equity
-179.12%
Trailing 12-Months
Asset Growth
-28.53%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$8.83
▲(225.83% Upside)
Technical Analysis
Nektar Therapeutics
―
Aldeyra Therapeutics
―
Larimar Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Ownership Overview
32.26% Insiders
6.70% Mutual Funds
0.03% Other Institutional Investors
57.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---